Online citations, reference lists, and bibliographies.
← Back to Search

D2-40 And Calretinin—a Tissue Microarray Analysis Of 341 Malignant Mesotheliomas With Emphasis On Sarcomatoid Differentiation

Marc Hinterberger, T. Reineke, M. Storz, W. Weder, P. Vogt, H. Moch
Published 2007 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Anti-calretinin antibodies are useful to differentiate adenocarcinomas from malignant mesotheliomas of the lung. Therefore, calretinin expression is rarely reported for sarcomatoid mesotheliomas. Anti-podoplanin antibodies (eg D2-40) react with lymphatic endothelia, Kaposi's sarcoma, lymphangioma and mesotheliomas. For the interpretation of spindle cell lesions of the pleura, knowledge of calretinin and D2-40 expression frequencies in sarcomatoid mesothelioma is desirable. To systematically investigate the sensitivity of calretinin and D2-40 antibodies in epithelioid and sarcomatoid areas of malignant mesotheliomas, a tissue microarray with 341 malignant mesotheliomas, including 112 epithelioid, 46 sarcomatoid and 183 biphasic tumors was constructed. Epithelioid and sarcomatoid differentiated tumor areas were clearly separated within the tissue microarray. Expression of calretinin and D2-40 was separately studied in epithelioid and sarcomatoid areas by immunohistochemistry. Calretinin expression was found in 91% of epithelioid and 57% of sarcomatoid tumor areas. D2-40 immunostaining was present in 66% of the epithelioid and 30% of the sarcomatoid tumor areas. A combination of calretinin and D2-40 increased the sensitivity in epithelioid tumor areas to 0.96 and in sarcomatoid tumor areas to 0.66. These data indicate that a combination of calretinin and D2-40 will improve diagnostic accuracy for spindle cell lesions of the pleura, whereas almost all epithelioid mesotheliomas are identified by calretinin alone.
This paper references
10.1067/MTC.2002.124242
Synovial sarcoma of the pleura: a clinical and pathologic study of three cases.
A. Colwell (2002)
10.1007/BF01606540
Diagnostic tools for differentiating pleural mesothelioma from lung adenocarcinoma in paraffin embedded tissue
H. Moch (2005)
10.1097/00000478-199712000-00003
The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval.
J. R. Riera (1997)
10.1038/modpathol.3880543
Monoclonal Antibody D2-40, a New Marker of Lymphatic Endothelium, Reacts with Kaposi's Sarcoma and a Subset of Angiosarcomas
H. Kahn (2002)
10.1097/00129039-200503000-00012
Comparison of Monoclonal Versus Polyclonal Calretinin Antibodies for Immunohistochemical Diagnosis of Malignant Mesothelioma
L. Granville (2005)
10.1016/S0344-0338(96)80208-1
The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type.
V. Gotzos (1996)
10.1038/modpathol.3800120
Validation of tissue microarray technology in ovarian carcinoma
D. Rosen (2004)
10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D
Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade
A. Nocito (2001)
10.1097/00000478-200105000-00007
Calretinin and Other Mesothelioma Markers in Synovial Sarcoma: Analysis of Antigenic Similarities and Differences With Malignant Mesothelioma
M. Miettinen (2001)
10.1007/s00428-003-0833-z
Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression
F. Jourdan (2003)
10.1007/BF03032608
Poorly differentiated synovial sarcoma: A case report
F. Cappello (2009)
10.1002/ijc.1385
Tissue microarrays (TMAs) for high‐throughput molecular pathology research
A. Nocito (2001)
10.1016/S0002-9440(10)64075-8
Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors.
A. Hoos (2001)
10.1097/00000478-199609000-00001
Calretinin: a novel immunocytochemical marker for mesothelioma.
C. Doglioni (1996)
10.1097/00000478-200308000-00001
The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (2003)
10.1046/j.1365-2559.2000.00770.x
HBME‐1, MOC‐31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma
Oates (2000)
Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
N. Ordóñez (1998)
10.1002/ijc.20656
Characterization of human PA2.26 antigen (T1α–2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas
Ester Martín-Villar (2005)
[Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies].
M. Chenard-Neu (1998)
10.1165/AJRCMB.19.1.2953
Evidence against a role of mouse, rat, and two cloned human t1alpha isoforms as a water channel or a regulator of aquaporin-type water channels.
T. Ma (1998)
10.1016/J.HUMPATH.2003.11.013
The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
N. Ordóñez (2004)
Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.
K. Amin (1995)
10.1038/modpathol.3880018
Value of the Mesothelium-Associated Antibodies Thrombomodulin, Cytokeratin 5/6, Calretinin, and CD44H in Distinguishing Epithelioid Pleural Mesothelioma from Adenocarcinoma Metastatic to the Pleura
P. Cury (2000)
10.1136/jcp.55.9.662
Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies
A. S. Abutaily (2002)
10.1097/00125480-200101000-00002
Tissue Microarrays: What Will They Bring to Molecular and Anatomic Pathology?
H. Moch (2001)
10.1046/j.1365-2559.1998.00349.x
E‐cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma
Leers (1998)
Expression of mesothelial markers in malignant mesotheliomas: an immunohistochemical evaluation of 173 cases.
I. Soomro (2005)
10.1038/sj.bjc.6690393
Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours
A. Marks (1999)
10.1007/s00428-005-0059-3
Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases
A. Knuuttila (2005)
10.1043/0003-9985(2003)127<85:PPS>2.0.CO;2
Primary pleural synovial sarcoma. A case report and review of the literature.
S. B. Ng (2003)
10.1016/S0002-9440(10)63075-1
Tissue microarrays for rapid linking of molecular changes to clinical endpoints.
J. Torhorst (2001)
10.1046/j.1365-2559.2003.01556.x
Biopsy of a biopsy: validation of immunoprofiling in gastric cancer biopsy tissue microarrays
C. Gulmann (2003)
10.1038/modpathol.3800560
Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma
B. Bode (2006)
10.1016/J.HUMPATH.2005.01.019
D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma.
N. Ordóñez (2005)
10.1097/00125480-199801000-00052
Calretinin: a novel tool for diagnostic immunohistochemistry.
A. D. Dei Tos (1998)
10.1053/S0046-8177(03)00339-3
Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples.
A. Lugli (2003)
10.1038/NM0798-844
Tissue microarrays for high-throughput molecular profiling of tumor specimens
J. Kononen (1998)
10.1046/j.1365-2559.2003.01583.x
Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study
D. Lucas (2003)
10.1046/j.1365-2559.1997.2150833.x
Anti‐cytokeratin 5/6: a positive marker for epithelioid mesothelioma
J. Clover (1997)
10.1080/00313020120038728
SYNOVIAL SARCOMA AND MALIGNANT MESOTHELIOMA OF THE PLEURA: REVIEW, DIFFERENTIAL DIAGNOSIS AND POSSIBLE ROLE OF APOPTOSIS
F. Cappello (2001)
10.1136/JCP.54.10.766
Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry.
F. Roberts (2001)
10.1016/S0002-9440(10)62311-5
Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors.
V. Schacht (2005)
10.1053/HUPA.2001.24329
Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
C. Comin (2001)
10.1038/labinvest.3780204
Validation of Tissue Microarray Technology in Breast Carcinoma
R. Camp (2000)
10.1038/modpathol.3800259
Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma
Albert Y Chu (2005)
10.1007/s007950200013
Synovial sarcoma arising from the pleura: a case report with ultrastructural and immunohistological studies
H. Hirano (2002)
10.1309/XL6K-8E62-9FLD-V8Q8
Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
F. Roberts (2001)
Tissue microarrays for gene amplification surveys in many different tumor types.
P. Schraml (1999)
10.1002/path.893
Tissue microarray (TMA) technology: miniaturized pathology archives for high‐throughput in situ studies
L. Bubendorf (2001)
10.1078/0344-0338-00502
Primary poorly differentiated monophasic synovial sarcoma of the lung. A case report with immunohistochemical and genetic studies.
Y. Mikami (2003)
10.1309/QHCA-8594-TA7P-0DVQ
An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma.
U. Brockstedt (2000)
10.1111/j.1365-2559.2005.02098.x
Expression of D2‐40 in lymphatic endothelium of normal tissues and in vascular tumours
M. Fukunaga (2005)
10.1097/00000478-200101000-00004
Immunohistochemical Panels For Differentiating Epithelial Malignant Mesothelioma From Lung Adenocarcinoma: A Study With Logistic Regression Analysis
R. Carella (2001)
10.1007/BF01606427
Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: immunohistochemical findings
H. Moch (2005)
10.1097/00000478-200302000-00002
Expression of Calretinin, Thrombomodulin, Keratin 5, and Mesothelin in Lung Carcinomas of Different Types: An Immunohistochemical Analysis of 596 Tumors in Comparison With Epithelioid Mesotheliomas of the Pleura
M. Miettinen (2003)
10.1002/1097-0142(20011115)92:10<2727::AID-CNCR1627>3.0.CO;2-B
The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas
T. Tot (2001)
10.1016/J.EJIM.2004.08.004
Primary synovial sarcoma of the pleura: beware of misdiagnosis.
H. Vohra (2004)
Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications.
M. Carbone (2002)



This paper is referenced by
10.1097/PAI.0b013e31829b6fbd
Value of Calretinin Immunostaining in Diagnostic Pathology: A Review and Update
N. Ordóñez (2014)
10.1016/j.lungcan.2009.12.014
The clinical significance of the tumor cell D2-40 immunoreactivity in non-small cell lung cancer.
Kyuichi Kadota (2010)
D 2-40 expression in ALK-positive anaplastic large cell lymphoma resembles CD 30 expression : a potential diagnostic pitfall
Yingjie Liu (2017)
10.1097/PAI.0b013e3181da8387
Value of D2-40 in the Differential Diagnosis of Pleural Neoplasms With Emphasis on Its Positivity in Solitary Fibrous Tumor
Y. Hu (2010)
10.1016/B978-1-4160-5766-6.00015-7
Chapter 11 – Immunohistology of the Mediastinum
M. R. Wick (2011)
True Identity by Immunohistochemistry
A. Bahrami (2008)
10.1038/bjc.2014.117
CD74: a new prognostic factor for patients with malignant pleural mesothelioma
C. Otterstrom (2014)
10.1016/j.humpath.2020.08.005
The potential utility of GATA3 for diagnosis of malignant pleural mesotheliomas.
Sarita Prabhakaran (2020)
10.1136/bmjopen-2017-021063
Clustering of malignant pleural mesothelioma in asbestos factories: a subgroup analysis in a 29-year follow-up study to identify high-risk industries in Taiwan
L. Lee (2018)
10.1016/j.prp.2009.06.001
Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
H. Deniz (2009)
10.1016/j.ejca.2010.09.044
Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis.
Roy Sidi (2011)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1016/B978-0-443-06652-8.50017-X
Chapter 11 – Immunohistology of Lung and Pleural Neoplasms
S. Hammar (2006)
10.1159/000339586
The Diagnostic Utility of D2-40, Calretinin, CK5/6, Desmin and MOC-31 in the Differentiation of Mesothelioma from Adenocarcinoma in Pleural Effusion Cytology
T. Hyun (2012)
10.1016/j.humpath.2017.07.015
The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
A. Marchevsky (2017)
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma
Aliya N. Husain (2017)
10.1002/dc.21340
Podoplanin is a useful marker for identifying mesothelioma in malignant effusions
Atef N Hanna (2010)
10.1016/j.prp.2013.09.002
Use of automated image analysis in evaluation of Mesothelioma Tissue Microarray (TMA) from National Mesothelioma Virtual Bank.
W. Amin (2014)
10.1245/s10434-015-4498-z
Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray
M. Deraco (2015)
10.1007/978-3-030-16884-1_8
Tissue and Circulating Biomarkers in Mesothelioma
Paolo Andrea Zucali (2019)
10.1378/chest.12-0123
Immunohistochemistry: applications to the evaluation of lung and pleural neoplasms: part 2.
H. Mani (2012)
10.21037/tlcr.2019.11.29
Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
D. Chapel (2020)
10.1111/j.1365-2559.2009.03322.x
Caveolin‐1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma
V. Amatya (2009)
10.1097/JTO.0000000000000055
PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy
B. Bitanihirwe (2014)
10.1007/978-0-387-72114-9_12
Neoplasms of the Pleura
S. Hammar (2008)
10.1111/j.1365-2559.2009.03298.x
Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma
Y. Takeshima (2009)
10.1043/1543-2165(2008)132[326:UTTIBI]2.0.CO;2
Undifferentiated tumor: true identity by immunohistochemistry.
Armita Bahrami (2008)
10.3390/cells9040888
Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the “Universal” CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2
Taiji Kuwata (2020)
10.5858/arpa.2017-0124-RA
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
A. Husain (2018)
10.1016/j.lungcan.2009.01.011
Accuracy of pathological diagnosis of mesothelioma cases in Japan: clinicopathological analysis of 382 cases.
Y. Takeshima (2009)
10.1016/j.ejcts.2009.08.027
Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.
Alexandra Schramm (2010)
10.1097/01.XEJ.0000429917.73672.9b
D2-40, combined with calretinin, WT-1, CEA, and TTF-1, an immunohistochemical panel for differentiating malignant pleural mesothelioma from lung adenocarcinoma
Ghada E. Esheba (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar